Mumbai, March 5 -- Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in Hematopoietic Stem Cell Transplantation (HSCT) and kidney transplant patients.
Sharvil Patel, MD of Zydus Lifesciences, said, "The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions. Our mission is to ensure that transplant patients get access to affordable, life-saving treatment."
CMV infection remains one of the most serious complications in transplant ...